http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 15 May 2026 16:32:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Emmaus+Life+Sciences%2C+++++For%3A+May+15/26506424.html si-local-file:///var/storage/secattach/20260515/26506424.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Emmaus+Life+Sciences%2C+++++For%3A+May+15/26506424.html Fri, 15 May 2026 16:32:00 -0400 EMMA O.05242772 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Emmaus+Life+Sciences%2C+++++For%3A+May+15/26506424.html si-local-file:///var/storage/secattach/20260515/26506424.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Emmaus+Life+Sciences%2C+++++For%3A+May+15/26506424.html Fri, 15 May 2026 16:32:00 -0400 EMMA O.05242772 http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26504486.html <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three months ended March 31, 2026. </p><p> <b>Highlights</b> </p><p> “We realized an 18% decline in net revenues for three month ended March 31, 2026 as compared to the same period in 2025 primarily driven by a 33% decrease in U.S. sales amid ongoing competition from generic L-Glutamine. The decline was partially offset by a 94% increase in sales in the Middle East North Africa, http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26504486.html Fri, 15 May 2026 15:51:00 -0400 A.06822034 A.14320728 EMMA O.05242772 O.20026344 O.20250741 http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26504486.html <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three months ended March 31, 2026. </p><p> <b>Highlights</b> </p><p> “We realized an 18% decline in net revenues for three month ended March 31, 2026 as compared to the same period in 2025 primarily driven by a 33% decrease in U.S. sales amid ongoing competition from generic L-Glutamine. The decline was partially offset by a 94% increase in sales in the Middle East North Africa, http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26504486.html Fri, 15 May 2026 15:51:00 -0400 A.06822034 A.14320728 EMMA O.05242772 O.20026344 O.20250741 http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26504486.html <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three months ended March 31, 2026. </p><p> <b>Highlights</b> </p><p> “We realized an 18% decline in net revenues for three month ended March 31, 2026 as compared to the same period in 2025 primarily driven by a 33% decrease in U.S. sales amid ongoing competition from generic L-Glutamine. The decline was partially offset by a 94% increase in sales in the Middle East North Africa, http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26504486.html Fri, 15 May 2026 15:51:00 -0400 A.06822034 A.14320728 EMMA O.05242772 O.20026344 O.20250741 http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26504486.html <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three months ended March 31, 2026. </p><p> <b>Highlights</b> </p><p> “We realized an 18% decline in net revenues for three month ended March 31, 2026 as compared to the same period in 2025 primarily driven by a 33% decrease in U.S. sales amid ongoing competition from generic L-Glutamine. The decline was partially offset by a 94% increase in sales in the Middle East North Africa, http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26504486.html Fri, 15 May 2026 15:51:00 -0400 A.06822034 A.14320728 EMMA O.05242772 O.20026344 O.20250741 http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26504486.html <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three months ended March 31, 2026. </p><p> <b>Highlights</b> </p><p> “We realized an 18% decline in net revenues for three month ended March 31, 2026 as compared to the same period in 2025 primarily driven by a 33% decrease in U.S. sales amid ongoing competition from generic L-Glutamine. The decline was partially offset by a 94% increase in sales in the Middle East North Africa, http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26504486.html Fri, 15 May 2026 15:51:00 -0400 A.06822034 A.14320728 EMMA O.05242772 O.20026344 O.20250741 http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26504486.html <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three months ended March 31, 2026. </p><p> <b>Highlights</b> </p><p> “We realized an 18% decline in net revenues for three month ended March 31, 2026 as compared to the same period in 2025 primarily driven by a 33% decrease in U.S. sales amid ongoing competition from generic L-Glutamine. The decline was partially offset by a 94% increase in sales in the Middle East North Africa, http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26504486.html Fri, 15 May 2026 15:51:00 -0400 A.06822034 A.14320728 EMMA O.05242772 O.20026344 O.20250741 http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26504486.html <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three months ended March 31, 2026. </p><p> <b>Highlights</b> </p><p> “We realized an 18% decline in net revenues for three month ended March 31, 2026 as compared to the same period in 2025 primarily driven by a 33% decrease in U.S. sales amid ongoing competition from generic L-Glutamine. The decline was partially offset by a 94% increase in sales in the Middle East North Africa, http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26504486.html Fri, 15 May 2026 15:51:00 -0400 A.06822034 A.14320728 EMMA O.05242772 O.20026344 O.20250741 http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26504486.html <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three months ended March 31, 2026. </p><p> <b>Highlights</b> </p><p> “We realized an 18% decline in net revenues for three month ended March 31, 2026 as compared to the same period in 2025 primarily driven by a 33% decrease in U.S. sales amid ongoing competition from generic L-Glutamine. The decline was partially offset by a 94% increase in sales in the Middle East North Africa, http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26504486.html Fri, 15 May 2026 15:51:00 -0400 A.06822034 A.14320728 EMMA O.05242772 O.20026344 O.20250741 http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26504486.html <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three months ended March 31, 2026. </p><p> <b>Highlights</b> </p><p> “We realized an 18% decline in net revenues for three month ended March 31, 2026 as compared to the same period in 2025 primarily driven by a 33% decrease in U.S. sales amid ongoing competition from generic L-Glutamine. The decline was partially offset by a 94% increase in sales in the Middle East North Africa, http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26504486.html Fri, 15 May 2026 15:51:00 -0400 A.06822034 A.14320728 EMMA O.05242772 O.20026344 O.20250741 http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26504486.html <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three months ended March 31, 2026. </p><p> <b>Highlights</b> </p><p> “We realized an 18% decline in net revenues for three month ended March 31, 2026 as compared to the same period in 2025 primarily driven by a 33% decrease in U.S. sales amid ongoing competition from generic L-Glutamine. The decline was partially offset by a 94% increase in sales in the Middle East North Africa, http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26504486.html Fri, 15 May 2026 15:51:00 -0400 A.06822034 A.14320728 EMMA O.05242772 O.20026344 O.20250741 http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26504486.html <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three months ended March 31, 2026. </p><p> <b>Highlights</b> </p><p> “We realized an 18% decline in net revenues for three month ended March 31, 2026 as compared to the same period in 2025 primarily driven by a 33% decrease in U.S. sales amid ongoing competition from generic L-Glutamine. The decline was partially offset by a 94% increase in sales in the Middle East North Africa, http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26504486.html Fri, 15 May 2026 15:51:00 -0400 A.06822034 A.14320728 EMMA O.05242772 O.20026344 O.20250741 http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26504486.html <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three months ended March 31, 2026. </p><p> <b>Highlights</b> </p><p> “We realized an 18% decline in net revenues for three month ended March 31, 2026 as compared to the same period in 2025 primarily driven by a 33% decrease in U.S. sales amid ongoing competition from generic L-Glutamine. The decline was partially offset by a 94% increase in sales in the Middle East North Africa, http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26504486.html Fri, 15 May 2026 15:51:00 -0400 A.06822034 A.14320728 EMMA O.05242772 O.20026344 O.20250741 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Emmaus+Life+Sciences%2C+++++For%3A+Mar+31/26504087.html si-local-file:///var/storage/secattach/20260515/26504087.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Emmaus+Life+Sciences%2C+++++For%3A+Mar+31/26504087.html Fri, 15 May 2026 15:04:00 -0400 EMMA O.05242772 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Emmaus+Life+Sciences%2C+++++For%3A+Mar+31/26504087.html si-local-file:///var/storage/secattach/20260515/26504087.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Emmaus+Life+Sciences%2C+++++For%3A+Mar+31/26504087.html Fri, 15 May 2026 15:04:00 -0400 EMMA O.05242772 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Emmaus+Life+Sciences%2C+++++For%3A+Apr+16++Filed+by%3A+DU+HENRY+HUY/26345659.html si-local-file:///var/storage/secattach/20260421/26345659.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Emmaus+Life+Sciences%2C+++++For%3A+Apr+16++Filed+by%3A+DU+HENRY+HUY/26345659.html Tue, 21 Apr 2026 19:12:00 -0400 EMMA O.05242772 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Emmaus+Life+Sciences%2C+++++For%3A+Apr+16++Filed+by%3A+DU+HENRY+HUY/26345659.html si-local-file:///var/storage/secattach/20260421/26345659.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Emmaus+Life+Sciences%2C+++++For%3A+Apr+16++Filed+by%3A+DU+HENRY+HUY/26345659.html Tue, 21 Apr 2026 19:12:00 -0400 EMMA O.05242772 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Emmaus+Life+Sciences%2C+++++For%3A+Apr+16/26331669.html si-local-file:///var/storage/secattach/20260417/26331669.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Emmaus+Life+Sciences%2C+++++For%3A+Apr+16/26331669.html Fri, 17 Apr 2026 17:16:00 -0400 EMMA O.05242772 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Emmaus+Life+Sciences%2C+++++For%3A+Apr+16/26331669.html si-local-file:///var/storage/secattach/20260417/26331669.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Emmaus+Life+Sciences%2C+++++For%3A+Apr+16/26331669.html Fri, 17 Apr 2026 17:16:00 -0400 EMMA O.05242772 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Emmaus+Life+Sciences%2C+++++For%3A+Apr+13/26312582.html si-local-file:///var/storage/secattach/20260414/26312582.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Emmaus+Life+Sciences%2C+++++For%3A+Apr+13/26312582.html Tue, 14 Apr 2026 16:43:00 -0400 EMMA O.05242772 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Emmaus+Life+Sciences%2C+++++For%3A+Apr+13/26312582.html si-local-file:///var/storage/secattach/20260414/26312582.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Emmaus+Life+Sciences%2C+++++For%3A+Apr+13/26312582.html Tue, 14 Apr 2026 16:43:00 -0400 EMMA O.05242772 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Emmaus+Life+Sciences%2C+++++For%3A+Mar+30/26245745.html si-local-file:///var/storage/secattach/20260331/26245745.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Emmaus+Life+Sciences%2C+++++For%3A+Mar+30/26245745.html Tue, 31 Mar 2026 08:01:00 -0400 EMMA O.05242772 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Emmaus+Life+Sciences%2C+++++For%3A+Mar+30/26245745.html si-local-file:///var/storage/secattach/20260331/26245745.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Emmaus+Life+Sciences%2C+++++For%3A+Mar+30/26245745.html Tue, 31 Mar 2026 08:01:00 -0400 EMMA O.05242772 http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Emmaus+Life+Sciences%2C+++++For%3A+Dec+31/26244648.html <p><a target="_blank" href="http://archive.fast-edgar.com/20260331/A32LUQ2DZW2RNZZ2222M2ZYLQJUDZZ22N282">http://archive.fast-edgar.com/20260331/A32LUQ2DZW2RNZZ2222M2ZYLQJUDZZ22N282</a></p> <p> Filed on: March 31, 2026 </p> http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Emmaus+Life+Sciences%2C+++++For%3A+Dec+31/26244648.html Tue, 31 Mar 2026 06:14:00 -0400 EMMA O.05242772